|Day's Range||41.63 - 41.87|
|52 Week Range||36.58 - 47.82|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.35%|
Remicade, a top-selling drugs for the treatment of inflammatory disorders, is losing market share after the loss of exclusivity in European markets in February 2015.
Bristol-Myers Squibb’s (BMY) latest drug Opdivo was the seventh drug to be approved by the FDA for the treatment of melanoma.
In 1Q17, Allergan's US Specialized Therapeutics segment revenues rose 14.1% to $1.48 billion, as compared to $1.30 billion in 1Q16.